NEW YORK – Indivumed and Biognosys on Tuesday said they are extending an existing partnership to apply immunopeptidomics to advance precision cancer drug discovery.
The companies will build on a 2019 partnership that focused on adding Biognosys' proteome-level data to Indivumed's IndivuType database to now include immunopeptide profiling with Biognosys' mass spectrometry technology.
For its part, Schlieren, Switzerland-based Biognosys will bring its Hyper Reaction Monitoring (HRM) mass spectrometry technology to quantify proteomes as well as its Spectronaut and SpectroMine data-analysis software to identify upwards of 10,000 different immunopeptides from minimal tumor samples. Meanwhile, using its global multiomics IndivuType database and nRavel analytics platform, Hamburg, Germany-based Indivumed will further validate the immunopeptide signatures that Biognosys identifies with these mass spec technologies.
The insights gleaned from these efforts are meant to help Indivumed's biopharma customers with their personalized cancer drug development programs. Several third-party companies are already applying the immunopeptidomics offering to their discovery efforts. Biognosys will present validation of its workflow's sensitivity and reproducibility at an upcoming conference, and Indivumed will also present a clinically relevant multiomic analysis at a separate conference.
"Biognosys' HRM technology uniquely addresses key challenges in immunopeptidomics research," Lukas Reiter, Biognosys' chief technology officer, said in a statement. "Using only small amounts of tissue, our optimized workflow provides deep and comprehensive biological insights on the immune system. We are thrilled to apply this solution on the valuable tissue samples from Indivumed and support drug discovery in areas of high unmet need."